Commercial-Scale ADC (Antibody-Drug Conjugate) CDMOs
ADC (Antibody-Drug Conjugate) manufacturers on CDMO Signal: 7 listed, 7 with a Signal Score. Together they have 46 FDA inspections on file (including 17 NAI, 27 VAI and 2 OAI), 2 FDA warning letters and 111 EMA/MHRA GMP certificates. Fewer than three are fully evidenced (all four score pillars and at least one ClinicalTrials.gov match), so this page does not name a top three. The score does not measure HPAPI containment, linker-payload chemistry, or whether antibody, payload and conjugation sit on one site. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology. This page is the commercial-scale filter: a high Signal Score or a broad ClinicalTrials.gov footprint. It is not a list of approved commercial products.
Antibody-drug conjugates pair a targeting antibody with a cytotoxic payload via a chemical linker — a three-component process that crosses biologics, small-molecule, and HPAPI (high-potency API) disciplines. Manufacturing demands purpose-built containment (typically OEB-5), wet-chemistry linker-payload synthesis, and validated bioconjugation under GMP.
Selecting an ADC CDMO turns on commercial bioconjugation track record, containment level, the linker / payload chemistries already in their book of business (vc, mc, glucuronide; MMAE, MMAF, DM1, DM4, Dxd, calicheamicin, PBDs, etc.), drug-substance + drug-product capability, and clean FDA + EMA/MHRA inspections. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 17 NAI (no action), 27 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: United States (34), Denmark (23), Italy (23), UNITED KINGDOM (22), Germany (13).
Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score
Showing contract manufacturers only.
| # | CDMO | Signal Score | Quality | FDA · GMP | Last FDA inspection | Capacity | Programs |
|---|---|---|---|---|---|---|---|
| 1 |
PR
Lexington, KY · Riverview, MI · Ahmedabad, IN
|
86.9 | 96.0 | 7 insp · 15 GMP | 2026-02-13 · VAI | — | — |
| 2 |
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
86.3 | 99.2 | 9 insp · 11 GMP | 2026-05-01 · NAI | Limited | — |
| 3 |
WB2
Shanghai, CN · Wuxi, CN
|
82.7 | 99.6 | 1 insp · 4 GMP | 2026-07-03 · VAI | — | — |
| 4 |
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
|
79.9 | 99.8 | 4 insp · 27 GMP | 2026-05-29 · NAI | Available | 2 programs |
| 5 |
BP
Latina, Italy
|
79.5 | 100.0 | 1 insp · 15 GMP | 2021-11-12 · VAI | — | — |
| 6 |
SK
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
|
79.5 | 100.0 | — | None on file | Available | — |
| 7 |
|
76.1 | 77.3 | 24 insp · 39 GMP | 2026-05-22 · VAI Warning letter 2025-11-20 |
— | — |